Overview Dividends

(MRUS) Merus BV - Ratings and Ratios

Exchange: NASDAQ • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: NL0011606264

Bispecific,Antibodies,Cancer,Clinical,Pipeline

MRUS EPS (Earnings per Share)

EPS (Earnings per Share) of MRUS over the last years for every Quarter: "2020-09-30": -0.64, "2020-12-31": -1.06, "2021-03-31": -0.28, "2021-06-30": -0.71, "2021-09-30": -0.39, "2021-12-31": -0.34, "2022-03-31": -0.43, "2022-06-30": -0.13, "2022-09-30": -0.53, "2022-12-31": -1.81, "2023-03-31": -0.86, "2023-06-30": -0.66, "2023-09-30": -0.43, "2023-12-31": -1.04, "2024-03-31": -0.59, "2024-06-30": -0.81, "2024-09-30": -1.46, "2024-12-31": -0.49, "2025-03-31": -1.4, "2025-06-30": -2.23,
EPS Growth (3Y CAGR): -67.15%
EPS Trend (3Y Correlation): -36.1%

MRUS Revenue

Revenue of MRUS over the last years for every Quarter: 2020-09-30: 8.57, 2020-12-31: 9.016, 2021-03-31: 8.35, 2021-06-30: 12.379, 2021-09-30: 13.669, 2021-12-31: 14.709, 2022-03-31: 11.655, 2022-06-30: 12.684, 2022-09-30: 6.581, 2022-12-31: 10.666, 2023-03-31: 13.499, 2023-06-30: 10.476, 2023-09-30: 11.033, 2023-12-31: 8.939, 2024-03-31: 7.889, 2024-06-30: 7.332, 2024-09-30: 11.772, 2024-12-31: 9.14, 2025-03-31: 26.488, 2025-06-30: 8.828,
Revenue Growth (3Y CAGR): 11.27%
Revenue Trend (3Y Correlation): 27.6%

Description: MRUS Merus BV

Merus BV is a clinical-stage immuno-oncology company developing innovative antibody therapeutics, focusing on bispecific antibodies to treat various cancers, including pancreatic adenocarcinoma, non-small cell lung cancer, and solid tumors. The companys pipeline includes several promising candidates, such as BIZENGRI, MCLA-158, and MCLA-129, targeting specific cancer types.

From a business perspective, Merus has established strategic collaborations with pharmaceutical giants like Eli Lilly, Ono Pharmaceutical, and Betta Pharmaceuticals, potentially validating its technology and providing future revenue streams. With a market capitalization of approximately $4.575 billion USD, Merus has a significant presence in the biotechnology sector.

To further analyze Merus performance, we can examine key performance indicators (KPIs) such as cash burn rate, research and development (R&D) expenses, and pipeline progression. A high cash burn rate could be a concern, given the companys negative return on equity (RoE) of -41.18%. However, the progress of its clinical trials and the potential for future collaborations or partnerships could offset this concern. Additionally, the companys ability to advance its pipeline and achieve regulatory milestones will be crucial in driving future growth.

Merus stock price has shown significant growth, with a 52-week high of $66.82 and a low of $34.89, indicating a potential increase in investor interest. To make an informed investment decision, its essential to monitor the companys progress in its clinical trials, as well as any updates on its collaborations and partnerships.

MRUS Stock Overview

Market Cap in USD 5,077m
Sub-Industry Biotechnology
IPO / Inception 2016-05-19

MRUS Stock Ratings

Growth Rating 76.6%
Fundamental 28.2%
Dividend Rating -
Return 12m vs S&P 500 12.3%
Analyst Rating 4.76 of 5

MRUS Dividends

Currently no dividends paid

MRUS Growth Ratios

Growth Correlation 3m 88.1%
Growth Correlation 12m 46%
Growth Correlation 5y 72.1%
CAGR 5y 49.89%
CAGR/Max DD 3y 1.09
CAGR/Mean DD 3y 3.49
Sharpe Ratio 12m -0.89
Alpha 0.13
Beta 0.680
Volatility 49.90%
Current Volume 634.8k
Average Volume 20d 589.5k
Stop Loss 64.1 (-4.2%)
Signal -0.94

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income (-385.5m TTM) > 0 and > 6% of Revenue (6% = 3.37m TTM)
FCFTA -0.19 (>2.0%) and ΔFCFTA -2.74pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 1203 % (prev 2062 %; Δ -858.5pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.32 (>3.0%) and CFO -312.8m > Net Income -385.5m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 8.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (71.1m) change vs 12m ago 14.95% (target <= -2.0% for YES)
Gross Margin -448.1% (prev -105.4%; Δ -342.7pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 6.01% (prev 3.94%; Δ 2.06pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -12.73 (EBITDA TTM -387.9m / Interest Expense TTM 30.8m) >= 6 (WARN >= 3)

Altman Z'' -11.43

(A) 0.69 = (Total Current Assets 768.3m - Total Current Liabilities 91.6m) / Total Assets 980.2m
(B) -1.25 = Retained Earnings (Balance) -1.22b / Total Assets 980.2m
warn (B) unusual magnitude: -1.25 — check mapping/units
(C) -0.42 = EBIT TTM -391.8m / Avg Total Assets 936.2m
(D) -8.65 = Book Value of Equity -1.20b / Total Liabilities 138.4m
Total Rating: -11.43 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 28.15

1. Piotroski 0.0pt = -5.0
2. FCF Yield -4.25% = -2.12
3. FCF Margin data missing
4. Debt/Equity 0.06 = 2.50
5. Debt/Ebitda -0.13 = -2.50
6. ROIC - WACC (= -56.19)% = -12.50
7. RoE -55.29% = -2.50
8. Rev. Trend 27.65% = 2.07
9. EPS Trend -36.08% = -1.80

What is the price of MRUS shares?

As of September 17, 2025, the stock is trading at USD 66.90 with a total of 634,796 shares traded.
Over the past week, the price has changed by -2.41%, over one month by +1.36%, over three months by +25.52% and over the past year by +33.27%.

Is Merus BV a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Merus BV (NASDAQ:MRUS) is currently (September 2025) a stock to sell. It has a ValueRay Fundamental Rating of 28.15 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of MRUS is around 79.01 USD . This means that MRUS is currently undervalued and has a potential upside of +18.1% (Margin of Safety).

Is MRUS a buy, sell or hold?

Merus BV has received a consensus analysts rating of 4.76. Therefore, it is recommended to buy MRUS.
  • Strong Buy: 13
  • Buy: 4
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the MRUS price?

Issuer Target Up/Down from current
Wallstreet Target Price 90.4 35.1%
Analysts Target Price 90.4 35.1%
ValueRay Target Price 88.1 31.7%

Last update: 2025-09-12 04:41

MRUS Fundamental Data Overview

Market Cap USD = 5.08b (5.08b USD * 1.0 USD.USD)
CCE Cash And Equivalents = 710.2m USD (Cash And Short Term Investments, last quarter)
P/S = 90.2991
P/B = 6.032
Beta = 1.19
Revenue TTM = 56.2m USD
EBIT TTM = -391.8m USD
EBITDA TTM = -387.9m USD
Long Term Debt = 46.9m USD (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 2.25m USD (from shortTermDebt, last quarter)
Debt = 49.1m USD (Calculated: Short Term 2.25m + Long Term 46.9m)
Net Debt = -431.8m USD (from netDebt column, last quarter)
Enterprise Value = 4.42b USD (5.08b + Debt 49.1m - CCE 710.2m)
Interest Coverage Ratio = -12.73 (Ebit TTM -391.8m / Interest Expense TTM 30.8m)
FCF Yield = -4.25% (FCF TTM -187.5m / Enterprise Value 4.42b)
FCF Margin = -333.5% (FCF TTM -187.5m / Revenue TTM 56.2m)
Net Margin = -685.6% (Net Income TTM -385.5m / Revenue TTM 56.2m)
Gross Margin = -448.1% ((Revenue TTM 56.2m - Cost of Revenue TTM 308.2m) / Revenue TTM)
Tobins Q-Ratio = -3.69 (set to none) (Enterprise Value 4.42b / Book Value Of Equity -1.20b)
Interest Expense / Debt = 62.70% (Interest Expense 30.8m / Debt 49.1m)
Taxrate = 21.0% (US default)
NOPAT = -391.8m (EBIT -391.8m, no tax applied on loss)
Current Ratio = 8.39 (Total Current Assets 768.3m / Total Current Liabilities 91.6m)
Debt / Equity = 0.06 (Debt 49.1m / last Quarter total Stockholder Equity 841.7m)
Debt / EBITDA = -0.13 (Net Debt -431.8m / EBITDA -387.9m)
Debt / FCF = -0.26 (Debt 49.1m / FCF TTM -187.5m)
Total Stockholder Equity = 697.3m (last 4 quarters mean)
RoA = -39.33% (Net Income -385.5m, Total Assets 980.2m )
RoE = -55.29% (Net Income TTM -385.5m / Total Stockholder Equity 697.3m)
RoCE = -52.65% (Ebit -391.8m / (Equity 697.3m + L.T.Debt 46.9m))
RoIC = -56.19% (NOPAT -391.8m / Invested Capital 697.3m)
WACC = unknown (E(5.08b)/V(5.13b) * Re(8.52%)) + (D(49.1m)/V(5.13b) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 96.97 | Cagr: 4.03%
Discount Rate = 8.52% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow -187.5m)
EPS Correlation: -36.08 | EPS CAGR: -67.15% | SUE: -3.04 | # QB: 0
Revenue Correlation: 27.65 | Revenue CAGR: 11.27%

Additional Sources for MRUS Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle